FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016607029> ?p ?o ?g. }

• W3016607029 endingPage "e202895" @default.
• W3016607029 startingPage "e202895" @default.
• W3016607029 abstract "Importance Immunotherapy using immune checkpoint inhibitors has been remarkably effective for treating multiple cancer types, and the gut microbiome is a possible factor affecting immune checkpoint inhibitor efficacy. However, the association between the gut microbiome and immune status of the tumor microenvironment remains unclear. Short-chain fatty acids (SCFAs) are major end product metabolites produced by the gut microbiota and have wide-ranging impacts on host physiology. Objective To evaluate fecal and plasma SCFAs in patients with solid cancer tumors treated with programmed cell death-1 inhibitors (PD-1i). Design, Setting, and Participants This was a prospective cohort biomarker study of patients with cancer who planned therapy with PD-1i at Kyoto University Hospital between July 2016 and February 2019. Data were analyzed from October 2019 to February 2020. Exposures Patients who were treated with nivolumab or pembrolizumab were classified into 2 groups based on their treatment response using Response Evaluation Criteria in Solid Tumors version 1.1: responders who achieved an objective response and nonresponders. Dietary information in terms of intake frequency was obtained. Concentrations of SCFAs in fecal and plasma samples collected before PD-1i administration were measured using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry. Main Outcomes and Measures The concentration of SCFAs and progression-free survival. Results Among 52 patients enrolled, the median (range) patient age was 67 (27-84) years, and 23 (44%) were women. Median (range) duration of follow-up of the survivors after administration of PD-1i was 2.0 (0.4–4.1) years. The overall response rate was 28.8%. High concentrations of some SCFAs were associated with longer progression-free survival. These included fecal acetic acid (hazard ratio [HR], 0.29; 95% CI, 0.15-0.54), propionic acid (HR, 0.08; 95% CI, 0.03-0.20), butyric acid (HR, 0.31; 95% CI, 0.16-0.60), valeric acid (HR, 0.53; 95% CI, 0.29-0.98), and plasma isovaleric acid (HR, 0.38; 95% CI, 0.14-0.99). Conclusions and Relevance Results of this study suggest that fecal SCFA concentrations may associated with PD-1i efficacy; thus, SCFAs may be the link between the gut microbiota and PD-1i efficacy. Because fecal examinations are completely noninvasive, they may be applicable for routine monitoring of patients." @default.
• W3016607029 created "2020-04-24" @default.
• W3016607029 creator A5005558291 @default.
• W3016607029 creator A5008673414 @default.
• W3016607029 creator A5015494958 @default.
• W3016607029 creator A5022854492 @default.
• W3016607029 creator A5034777038 @default.
• W3016607029 creator A5039994262 @default.
• W3016607029 creator A5054704526 @default.
• W3016607029 creator A5071597870 @default.
• W3016607029 creator A5075898374 @default.
• W3016607029 date "2020-04-16" @default.
• W3016607029 modified "2023-10-17" @default.
• W3016607029 title "Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors" @default.
• W3016607029 cites W1968105193 @default.
• W3016607029 cites W1993037755 @default.
• W3016607029 cites W1999906527 @default.
• W3016607029 cites W2003342633 @default.
• W3016607029 cites W2037447742 @default.
• W3016607029 cites W2042647692 @default.
• W3016607029 cites W2060185417 @default.
• W3016607029 cites W2087292184 @default.
• W3016607029 cites W2097995306 @default.
• W3016607029 cites W2112121482 @default.
• W3016607029 cites W2128035403 @default.
• W3016607029 cites W2135232490 @default.
• W3016607029 cites W2144494558 @default.
• W3016607029 cites W2153162429 @default.
• W3016607029 cites W2254098989 @default.
• W3016607029 cites W2295131371 @default.
• W3016607029 cites W2620472170 @default.
• W3016607029 cites W2765314233 @default.
• W3016607029 cites W2766903152 @default.
• W3016607029 cites W2782311151 @default.
• W3016607029 cites W2782333299 @default.
• W3016607029 cites W2884838967 @default.
• W3016607029 cites W2886232222 @default.
• W3016607029 cites W2890880452 @default.
• W3016607029 cites W2912557487 @default.
• W3016607029 cites W2922350535 @default.
• W3016607029 cites W2953093188 @default.
• W3016607029 cites W2979096324 @default.
• W3016607029 cites W4240188022 @default.
• W3016607029 cites W4251118501 @default.
• W3016607029 doi "https://doi.org/10.1001/jamanetworkopen.2020.2895" @default.
• W3016607029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7163404" @default.
• W3016607029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32297948" @default.
• W3016607029 hasPublicationYear "2020" @default.
• W3016607029 type Work @default.
• W3016607029 sameAs 3016607029 @default.
• W3016607029 citedByCount "166" @default.
• W3016607029 countsByYear W30166070292020 @default.
• W3016607029 countsByYear W30166070292021 @default.
• W3016607029 countsByYear W30166070292022 @default.
• W3016607029 countsByYear W30166070292023 @default.
• W3016607029 crossrefType "journal-article" @default.
• W3016607029 hasAuthorship W3016607029A5005558291 @default.
• W3016607029 hasAuthorship W3016607029A5008673414 @default.
• W3016607029 hasAuthorship W3016607029A5015494958 @default.
• W3016607029 hasAuthorship W3016607029A5022854492 @default.
• W3016607029 hasAuthorship W3016607029A5034777038 @default.
• W3016607029 hasAuthorship W3016607029A5039994262 @default.
• W3016607029 hasAuthorship W3016607029A5054704526 @default.
• W3016607029 hasAuthorship W3016607029A5071597870 @default.
• W3016607029 hasAuthorship W3016607029A5075898374 @default.
• W3016607029 hasBestOaLocation W30166070291 @default.
• W3016607029 hasConcept C121608353 @default.
• W3016607029 hasConcept C126322002 @default.
• W3016607029 hasConcept C143121216 @default.
• W3016607029 hasConcept C143998085 @default.
• W3016607029 hasConcept C203014093 @default.
• W3016607029 hasConcept C2777701055 @default.
• W3016607029 hasConcept C2780030458 @default.
• W3016607029 hasConcept C2780057760 @default.
• W3016607029 hasConcept C3019978661 @default.
• W3016607029 hasConcept C526805850 @default.
• W3016607029 hasConcept C539455810 @default.
• W3016607029 hasConcept C60644358 @default.
• W3016607029 hasConcept C71924100 @default.
• W3016607029 hasConcept C86803240 @default.
• W3016607029 hasConceptScore W3016607029C121608353 @default.
• W3016607029 hasConceptScore W3016607029C126322002 @default.
• W3016607029 hasConceptScore W3016607029C143121216 @default.
• W3016607029 hasConceptScore W3016607029C143998085 @default.
• W3016607029 hasConceptScore W3016607029C203014093 @default.
• W3016607029 hasConceptScore W3016607029C2777701055 @default.
• W3016607029 hasConceptScore W3016607029C2780030458 @default.
• W3016607029 hasConceptScore W3016607029C2780057760 @default.
• W3016607029 hasConceptScore W3016607029C3019978661 @default.
• W3016607029 hasConceptScore W3016607029C526805850 @default.
• W3016607029 hasConceptScore W3016607029C539455810 @default.
• W3016607029 hasConceptScore W3016607029C60644358 @default.
• W3016607029 hasConceptScore W3016607029C71924100 @default.
• W3016607029 hasConceptScore W3016607029C86803240 @default.
• W3016607029 hasIssue "4" @default.
• W3016607029 hasLocation W30166070291 @default.
• W3016607029 hasLocation W30166070292 @default.
• W3016607029 hasLocation W30166070293 @default.

• next